Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Pharmacokinetics
Published in: Clinical Pharmacokinetics 12/2018

01-12-2018 | Review Article

Clinical Pharmacokinetics of Atypical Antipsychotics: An Update

Authors: Massimo Carlo Mauri, Silvia Paletta, Chiara Di Pace, Alessandra Reggiori, Giovanna Cirnigliaro, Isabel Valli, Alfredo Carlo Altamura

Published in: Clinical Pharmacokinetics | Issue 12/2018

Login to get access

Abstract

Therapeutic drug monitoring studies have generally concentrated on controlling compliance and avoiding side effects by maintaining long-term exposure to minimally effective blood concentrations. The rationale for using therapeutic drug monitoring in relation to second-generation antipsychotics is still being discussed at least with regard to the real clinical utility, but there is evidence that it can improve efficacy, especially when patients do not respond or develop side effects using therapeutic doses. Furthermore, drug plasma concentration determinations can be of some utility in medico-legal problems. This review concentrates on the clinical pharmacokinetic data related to clozapine, risperidone, paliperidone, olanzapine, quetiapine, amisulpride, ziprasidone, aripiprazole, sertindole, asenapine, iloperidone, lurasidone, brexpiprazole and cariprazine and briefly considers the main aspects of their pharmacodynamics. Optimal plasma concentration ranges are proposed for clozapine, risperidone, paliperidone and olanzapine because the studies of quetiapine, amisulpride, asenapine, iloperidone and lurasidone provide only limited information and there is no direct evidence concerning ziprasidone, aripiprazole, sertindole, brexpiprazole and cariprazine: the few reported investigations need to be confirmed and extended.
Literature
1.
2.
McCutcheon R, Beck K, D’Ambrosio E, Donocik J, Gobjila C, Jauhar S, Kaar S, Pillinger T, Reis Marques T, Rogdaki M, Howes OD. Antipsychotic plasma levels in the assessment of poor treatment response in schizophrenia. Acta Psychiatr Scand. 2018;137(1):39–46.PubMed
3.
Buur-Rasmussen B, Brosen K. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol. 1999;9:453–9.PubMed
4.
Prior TI, Chue PS, Tibbo P, Baker GB. Drug metabolism and atypical antipsychotics. Eur Neuropsychopharmacol. 1999;9:301–9.PubMed
5.
Mauri MC, Volonteri L, Dell’Osso B, Regispani F, Papa P, Baldi ML, Bareggi SR. Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol. 2003;23(6):660–4.PubMed
6.
Steen NE, Aas M, Simonsen C, Dieset I, Tesli M, Nerhus M, Gardsjord E, Mørch R, Agartz I, Melle I, Ueland T, Spigset O, Andreassen OA. Serum levels of second-generation antipsychotics are associated with cognitive function in psychotic disorders. World J Biol Psychiatry. 2017;18(6):471–82.PubMed
7.
Preskorn SH. Therapeutic drug monitoring (TDM) in psychiatry (part I): why studies attempting to correlate drug concentration and antidepressant response don’t work. J Psychiatr Pract. 2014;20(2):133–7.PubMed
8.
Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, Eckermann G, Egberts K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017. Pharmacopsychiatry. 2018;51(1–02):9–62.PubMed
9.
Meltzer HY, Bastani B, Ramirez L, Matsubara S. Clozapine: new research on efficacy and mechanism of action. Eur Arch Psychiatry Neurol Sci. 1989;238:332–9.PubMed
10.
Meltzer HY. The mechanism of action of clozapine in relation to its clinical advantages. In: Meltzer HY, editor. Novel antipsychotic drugs. New York: Raven Press Ltd; 1992. p. 1–13.
11.
Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response treatment-refractory schizophrenic patients. Am J Psychiatry. 1991;148:231–5.PubMed
12.
Hasegawa M, Gutierrez-Esteinou R, Way L, Meltzer HY. Relationship between clinical efficacy and clozapine concentration in plasma in schizophrenia: effect of smocking. J Clin Psychopharmacol. 1993;13:383–90.PubMed
13.
Potkin SG, Bera R, Gulasekaram B, Costa J, Hayes S, Jin Y, Richmond G, Carreon D, Sitanggan K, Gerber B, Telford J, Plon L, Plon H, Park L, Chang YJ, Oldroyd J, Cooper T. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry. 1994;55:133–6.PubMed
14.
Kronig MH, Munne RA, Szymansky S, Safferman AZ, Pollack S, Cooper T, Kane JM, Lieberman JA. Plasma clozapine levels and clinical response for treatment-refractory schizophrenic patients. Am J Psychiatry. 1995;152:179–82.PubMed
15.
Mauri MC, Volonteri LS, Fiorentini A, Invernizzi G, Bareggi SR. Clinical outcome and plasma levels of clozapine and norclozapine in drug-resistant schizophrenic patients. Schizophr Res. 2004;66:197–8.PubMed
16.
Freeman DJ, Oyewumi LK. Will routine therapeutic drug monitoring have a place in clozapine therapy? Clin Pharmacokinet. 1997;32:95–100.
17.
Khan AY, Preskorn SH. Examining concentration-dependence toxicity of clozapine: role of therapeutic drug monitoring. J Psychiat Pract. 2005;11:289–301.
18.
Ackenheil VM, Brau H, Burkhart A, Franke A, Pacha W. Antipsychotic efficacy in relation to plasma levels of clozapine. Arzneimttelforschung. 1976;26:1156–8.
19.
Thorup M, Fog R. Clozapine tretment of schizophrenic patients: plasma concentration and coagulation factors. Acta Psychiatr Scand. 1977;66:123–6.
20.
Brau VH, Burkhart A, Pacha W, Ackenheil VM. Relationships between effects and plasma levels of clozapine. Arzneimttelforschung. 1978;28:1300.
21.
Bell R, Mc Laren A, Galanos J, Copolov D. The clinical use of plasma clozapine levels. Aust N Z J Psychiatry. 1998;32:567–74.PubMed
22.
Volpicelli SA, Centorrino F, Puopolo PR, Kando J, Frankenburg FR, Baldessarrini RJ, Flood JG. Determination of clozapine, norclozapine and clozapine-N-oxide in serum by liquid chromatography. Clin Chem. 1993;39:1656–9.PubMed
23.
Palego L, Biondi L, Giannaccini G, Sarno N, Elmi S, Ciapparelli A, Cassano GB, Lucacchini A, Martini C, Dell’Osso L. Clozapine, norclozapine plasma levels, their sum and ratio in 50 psychotic patients. Influence of patient-related veriables. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26:473–80.PubMed
24.
Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:799–812.
25.
Llorca PM, Lancon C, Disdier B, Farisse J, Sapin C, Auquier P. Effectiveness of clozapine in neuroleptic-resistent schizophrenia: clinical response and plasma concentrations. J Psychiatry Neurosci. 2002;27:30–7.PubMedPubMedCentral
26.
Kay SR, Fiszbein A, Opler LA. the positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261–76.PubMed
27.
Guy W. ECDEU Assessment manual for psychopharmacology. DHEW Publication; 1976. pp. 76–388.
28.
Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with clorpromazine. Arch Gen Psychiatry. 1988;45:789–96.PubMed
29.
Jann MW, Grimsley SR, Gray EC, Chang WH. Pharmacokinetics and pharmacodynamics of clozapine. Clin Pharmacokinetic. 1993;24:161–76.
30.
Choc MG, Lehr RG, Hsuan F, Honigfeld G, Smith HT, Borison R, Volavka J. Multiple-dose pharmacokinetics of clozapine in patients. Pharm Res. 1987;4:402–5.PubMed
31.
Choc MG, Hsuan F, Honigfeld G, Robinson WT, Ereshefsky L, Crismon ML, Saklad SR, Hirschowitz J, Wagner R. Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res. 1990;7:347–51.PubMed
32.
Fabrazzo M, La Pia S, Monteleone P, Esposito G, Pinto A, De Simone L, Bencivenga R, Maj M. Is the time corse of clozapine response correlated to the time course of clozapine plasma levels? A one-year prospective study in drug-resistant patients with schizophrenia. Neuropsychopharmacology. 2002;27:1050–5.PubMed
33.
Miller DD, Fleming F, Holman TL, Perry P. Plasma clozapine concentrations as a predictor of clinical response: a follow-up study. J Clin Psychiatry. 1994;55:117–21.PubMed
34.
Schulte P. What is an adequate trial with clozapine? Therapeutic drug monitoring and time to response in treatment-refractory schizophrenia. Clin Pharmacokinet. 2003;42:607–18.PubMed
35.
Eap CB, Bender S, Jaquenoud SE, Cucchia G, Jonzier-Perey M, Baumann P, Allorge D, Broly F. Nonresponse to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene. J Clin Psychopharmacol. 2004;24:214–9.PubMed
36.
Akamine Y, Sugawara-Kikuchi Y, Uno T, Shimizu T, Miura M. Quantification of the steady-state plasma concentrations of clozapine and N-desmethylclozapine in Japanese patients with schizophrenia using a novel HPLC method and the effects of CYPs and ABC transporters polymorphisms. Ann Clin Biochem. 2017;54(6):677–85.PubMed
37.
Tóth K, Csukly G, Sirok D, Belic A, Kiss Á, Háfra E, Déri M, Menus Á, Bitter I, Monostory K. Potential role of patients’ CYP3A-status in clozapine pharmacokinetics. Int J Neuropsychopharmacol. 2017;20(7):529–37.PubMedPubMedCentral
38.
Wohkittel C, Gerlach M, Taurines R, Wewetzer C, Unterecker S, Burger R, Schreck D, Mehler-Wex C, Romanos M, Egberts K. Relationship between clozapine dose, serum concentration, and clinical outcome in children and adolescents in clinical practice. J Neural Transm (Vienna). 2016;123(8):1021–31.PubMed
39.
Nordstrom AL, Farde L, Nyberg S, Karlsson P, Halldin C, Sedvall G. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: A PET study of schizophrenic patients. Am J Psychiatry. 1995;152:1444–9.PubMed
40.
Seeman P, Van Tool HHM. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the D2 or D4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol Mol Pharmacol. 1995;291:59–66.
41.
Zhao AL, Zhao JP, Zhang YH, Xue ZM, Chen JD, Chen XG. Dopamine D4 receptor gene exon III polymorphism and interindividual variation in response to clozapine. Int J Neurosci. 2005;115:1539–47.PubMed
42.
Molins C, Carceller-Sindreu M, Navarro H, Carmona C, Piñeiro M, Martínez E, Álvarez E, Portella MJ. Plasma ratio of clozapine to N-desmethylclozapine can predict cognitive performance in treatment-resistant psychotic patients. Psychiatry Res. 2017;258:153–7.PubMed
43.
Rabinowitz J, Davidson M. Risperidone versus haloperidol in long-term hospitalized chronic patients in a double blind randomized trial: a post hoc analysis. Schizophr Res. 2001;50:89–93.PubMed
44.
Emsley RA, Risperidone Working Group. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull. 1999;25:721–9.PubMed
45.
Peuskens J, Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995;166:712–26.PubMed
46.
Jansen PAJ, Niemegeers CJE, Awouters F. Schellekens KHL, Megens AAHP, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotics with serotonin-s2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther. 1988;244:685–93.
47.
Leysen JE, Gommeren W, Eens A, de Courcelles DDC, Stoof JC, Jansen PAJ. Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther. 1998;247:661–70.
48.
Ereshefsky L, Lacombe S. Pharmacological profile of risperidone. Can J Psychiatry. 1993;38(Suppl. 3):80–8.
49.
Mannens G, Huang ML, Meuldermans W, Hendrickx J, Woestenborghs R, Meibach R, Heykants J. Absorption, metabolism, and excretion of risperidone in humans. Drug Metab Disp. 1993;21:1134–41.
50.
Baldessarini RJ. In: Goodman LS, Gilman A. The pharmacological basis of therapeutics. 9th ed. McGraw-Hill; 1996. pp. 399–430.
51.
Schoretsanitis G, Stegmann B, Hiemke C, Gründer G, Schruers KR, Walther S, Lammertz SE, Haen E, Paulzen M. Pharmacokinetic patterns of risperidone-associated adverse drug reactions. Eur J Clin Pharmacol. 2016;72(9):1091–8.PubMed
52.
Paulzen M, Haen E, Stegmann B, Unterecker S, Hiemke C, Gründer G, Schoretsanitis G. Clinical response in a risperidone-mediated naturalistic sample: patients’ characteristics and dose-dependent pharmacokinetic patterns. Eur Arch Psychiatry Clin Neurosci. 2016;267(4):325–33.PubMed
53.
Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54:257–68.PubMed
54.
Vandenberghe F, Guidi M, Choong E, von Gunten A, Conus P, Csajka C, Eap CB. Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort. Clin Pharmacokinet. 2015;54(12):1259–72.PubMed
55.
Aravagiri M, Marder SR, Wirshing D, Wirshing WC. Plasma concentrations of risperidone and its 9-hydroxy metabolite and their relationship to dose in schizophrenic patients: simultaneous determination by a high performance liquid chromatography with electrochemical detection. Pharmacopsychiatry. 1998;31:102–9.PubMed
56.
Aravagiri M, Marder SR, Nuechterlein KH, Gitlin MJ. Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone. Ther Drug Monit. 2003;25:657–64.PubMed
57.
Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 1994;48:253–73.PubMed
58.
Heykants J, Hunag ML, Mannens G, Meuldermans W, Snoeck E, Van Beijstetveldt L, Van Peer A, Woestenborghs R. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry. 1994;55(Suppl.):13–7.
59.
Spina E, Avenoso A, Facciola G, Salemi M, Scordo MG, Ancione M, Madia AG, Perucca E. Relationship between plasma risperidone and 9-hydroxyrisperidone concentrations and clinical response in patients with schizophrenia. Psychopharmacology. 2001;153:238–43.PubMed
60.
Olesen OV, Licht RW, Thomsen E, Bruun T, Viftrup JE, Linnet K. Serum concentrations and side effects in psychiatric patients during risperidone therapy. Ther Drug Monit. 1998;20:380–4.PubMed
61.
Riedel M, Schwarz MJ, Strassing M, Spellmann A, Muller-Arends A, Weber K, Zach J, Muller N, Moller HJ. Risperidone plasma levels, clinical response and side-effects. Eur Arch Psychiatry Clin Neurosci. 2005;255:261–8.PubMed
62.
Mauri MC, Laini V, Boscati L, Rudelli R, Salvi V, Orlandi R, Papa P. Long term treatment of chronic schizophrenia with risperidone: a study with plasma levels. Eur Psychiatry. 2001;16:57–63.PubMed
63.
Chen PS, Yang YK, Su SF, Liao YC, Chang JW, Yeh TL. Correlation between scores on continuous performance test and plasma concentration for schizophrenic patients on risperidone. Psychiatry Clin Neurosci. 2004;58:168–72.PubMed
64.
Kelleher JP, Centorrino F, Albert MJ, Baldessarini RJ. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs. 2002;16:249–61.PubMed
65.
Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 2003;160:1125–32.PubMed
66.
Chue P, Eerdekens M, Augustyns I, Lachaux B, Molcan P, Eriksson L, Pretorius H, David AS. Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur Neuropsychopharmacol. 2005;15:111–7.PubMed
67.
Mannaert E, Vermeulen A, Remmerie B, Bouhours P, Levron JC. Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. Encephale. 2005;31:609–15.PubMed
68.
Mauri MC, Paletta S, Maffini M, Colasanti A, Dragogna F, Di Pace C, Altamura AC. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163–91.PubMedPubMedCentral
69.
Eerdekens M, Van Hove I, Remmerie B, Mannaert E. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia. Schizophr Res. 2004;70:91–100.PubMed
70.
Nesvag R, Hendset M, Refsum H, Tanum L. Serum concentrations of risperidone and 9-OH risperidone following intramuscular injection of long-acting risperidone compared with oral risperidone medication. Acta Psychiatr Scand. 2006;114:21–6.PubMed
71.
Castberg I, Spigset O. Serum concentrations of risperidone and 9-hydroxyrisperidone after administration of the long-acting injectable form of risperidone: evidence from a routine therapeutic drug monitoring service. Ther Drug Monit. 2005;27:103–6.PubMed
72.
Gefvert O, Eriksson B, Persson P, Helldin L, Bjorner A, Mannaert E, Remmerie B, Eerdekens M, Nyberg S. Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia. Int J Neuropsychopharmacol. 2005;8:27–36.PubMed
73.
Korell J, Green B, Remmerie B, Vermeulen A. Determination of plasma concentration reference ranges for risperidone and paliperidone. CPT Pharmacomet Syst Pharmacol. 2017;6(9):589–95.
74.
Odou P, Levron JC, Luyckx M, Brunet C, Robert H. Risperidone drug monitoring. Clin Drug Invest. 2000;19:283–92.
75.
Marder SR, Meibach R. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825–35.PubMed
76.
Darby JK, Pasta DJ, Elfand L, Dabiri L, Clark L, Herbert J. Risperidone dose and blood level variability: accumulation effects and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting. J Clin Psychopharmacol. 1997;17:478–84.PubMed
77.
Whitney Z, Boyda HN, Procyshyn RM, Elbe D, Black T, Eslami A, Barr AM. Therapeutic drug levels of second generation antipsychotics in youth: a systematic review. J Child Adolesc Psychopharmacol. 2015;25:234–45.PubMed
78.
Dos Santos-Júnior A, Tamascia ML, Lorenzetti R, Della Torre OH, Paes LA, Fontana TS, Ferreira-Neto AP, Henriques TB, Hyslop S, de Mello MP, Celeri EH, Dalgalarrondo P, Guerra-Júnior G. Serum concentration of risperidone and adverse effects in children and adolescents. J Child Adolesc Psychopharmacol. 2017;27(2):211–2.PubMed
79.
80.
Mauri MC, Reggiori A, Paletta S, Di Pace C, Altamura AC. Paliperidone for the treatment of schizophrenia and schizoaffective disorders: a drug safety evaluation. Exp Opin Drug Saf. 2017;16(3):365–79.
81.
Macaluso M, Oliver H, Sohail Z. Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder. Expert Opin Drug Metab Toxicol. 2017;13(8):871–9.PubMed
82.
Arakawa R, Ito H, Takano A, Takahashi H, Morimoto T, Sassa T, Ohta K, Kato M, Okubo Y, Suhara T. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology. 2008;197(2):229–35.PubMed
83.
Conley R, Gupta SK, Sathyan G. Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form. Curr Med Res Opin. 2006;22(10):1879–92.PubMed
84.
Citrome L. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability. Expert Opin Drug Metab Toxicol. 2012;8(7):873–88.PubMed
85.
Fowler JA, Bettinger TL, Argo TR. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia. Clin Ther. 2008;30(2):231–48.PubMed
86.
Janicak PG, Winans EA. Paliperidone ER: a review of the clinical trial data. Neuropsychiat Dis Treat. 2007;3(6):869–83.
87.
Spina E, Crupi R. Safety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia. J Cent Nerv Sys Dis. 2011;3:27–41.
88.
Tianmei S, Liang S, Yi L, Yun’Ai S, Chunmei G, Hongyan Z. Single-dose pharmacokinetics of paliperidone extended-release tablets in healthy Chinese subjects. Hum Psychopharmacol Clin Exp. 2010;25:404–9.
89.
Nazirizadeh Y, Vogel F, Bader W, Haen E, Pfuhlmann B, Gründer G, Paulzen M, Schwarz M, Zernig G, Hiemke C. Serum concentrations of paliperidone versus risperidone and clinical effects. Eur J Clin Pharmacol. 2010;66:797–803.PubMed
90.
Janssen Pharmaceuticals, Inc. Invega® Sustenna® (paliperidone palmitate). Full prescribing information. Titusville (NJ): Janssen Pharmaceuticals, Inc.; 2015.
91.
Carter NJ. Extended-release intramuscular paliperidone palmitate:a review of its use in the treatment of schizophrenia. Drugs. 2012;72(8):1137–60.PubMed
92.
Hoy SM, Scott LJ, Keating GM. Intramuscular paliperidone palmitate. CNS Drugs. 2010;24(3):227–44.PubMed
93.
Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia: results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol. 2010;13:635–47.PubMed
94.
Di Pace C, Paletta S, Reggiori A, Maffini M, Chirico M, Mauri MC, Altamura AC. Paliperidone “long-acting” and plasma levels along 1 year of maintenance therapy in schizophrania and schizoaffective disorders. Eur Neuropsychopharmacol. 2015;25(Suppl. 2):525.
95.
Berwaerts J, Liu Y, Gopal S, Nuamah I, Xu H, Savitz A, Coppola D, Alain Schotte A, Remmerie B, Eng C, Maruta N, Hough DW. Efficacy and safety of the 3-month formulation of paliperidone palmitate vs placebo for relapse prevention of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2015;72(8):830–9.PubMed
96.
Ravenstijn P, Remmerie B, Eng C, Savitz A, Samtani MN, Nuamah I, Chang CT, De Meulder M, Hough D, Gopal S. Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: a phase-1, single-dose, randomized, open-label study. J Clin Pharmacol. 2015;20(20):1–10.
97.
McCormack PL, Wiseman LR. Olanzapine: a review of its use in the management of bipolar disorder. Drugs. 2004;64:2709–26.PubMed
98.
Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipurski R, Wei H, Hamer RM. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160:1396–404.PubMed
99.
Lambert M, Haro JM, Novick D, Edgell ET, Kennedy L, Ratcliffe M, Naber D. Olanzapine vs other antipsychotics in actual out-patient settings: six months tolerability results from the European Schizophrenia Out-patient Health Outcomes study. Acta Psychiatr Scand. 2005;111:232–43.PubMed
100.
Duggan L, Fenton M, Rathbone J, Dardennes R, El-Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane Database Syst Rev. 2005;18:CD001359.
101.
Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO. Olanzapine: a basic science update. Br J Psychiatry. 1999;37:36–40.
102.
Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999;37:177–93.PubMed
103.
Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, Lemberger L. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997;25:81–93.PubMed
104.
Lu ML, Wu YX, Chen CH, Kuo PT, Chen YH, Lin CH, Wu TH. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor clinical efficacy in patients with schizophrenia. PLoS One. 2016;11(2):e0148539.PubMedPubMedCentral
105.
Kelly DL, Conley RR, Tamminga CA. Differential olanzapine plasma concentrations by sex in a fixed-dose study. Schizophr Res. 1999;40:101–4.PubMed
106.
Dusci LJ, Peter Hackett L, Fellows LM, Ilett KF. Determination of olanzapine in plasma by high-performance liquid chromatography using ultraviolet absorbance detection. J Chromatogr B Anal Technol Biomed Life Sci. 2002;773:191–7.
107.
Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol. 2001;21:14–20.PubMed
108.
Gex-Fabry M, Balant-Gorgia AE, Balant LP. Therapeutic drug monitoring of olanzapine: the combined effect of age, gender, smoking, and comedication. Ther Drug Monit. 2003;25:46–53.PubMed
109.
Bergemann N, Frick A, Parzer P, Kopitz J. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry. 2004;37:63–8.PubMed
110.
Mauri MC, Steinhilber CPC, Marino R, Invernizzi E, Fiorentini A, Cerveri G, Baldi ML, Barale F. Clinical outcome and olanzapine plasma levels in acute schizophrenia. Eur Psychiatry. 2005;20:55–60.PubMed
111.
Aravagiri M, Ames D, Wirshing WC, Marder SR. Plasma level monitoring of olanzapine in patients with schizophrenia: determination by high-performance liquid chromatography with electrochemical detection. Ther Drug Monit. 1997;19:307–13.PubMed
112.
Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit. 1999;21:87–90.PubMed
113.
Lane HY, Guo SC, Hwang TJ, Chen YS, Cheng JJ, Lee YC, Hong CJ, Hwu HG, Chang WH. Effects of olanzapine plasma concentrations on depressive symptoms in schizophrenia: a pilot study. J Clin Psychopharmacol. 2002;22:530–2.PubMed
114.
Skogh E, Reis M, Dahl ML, Lundmark J, Bengtsson F. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002;24:518–26.PubMed
115.
Fellows L, Ahmad F, Castle DJ, Dusci LJ, Bulsara MK, Ilett KF. Investigation of target plasma concentration–effect relationships for olanzapine in schizophrenia. Ther Drug Monit. 2003;25:682–9.PubMed
116.
Wright P, Lindborg SR, Birkett M, Meehan K, Jones B, Alaka K, Ferchland-Howe I, Pickard A, Taylor CC, Roth J, Battaglia J, Bitter I, Chouinard G, Morris PL, Breier A. Intramuscular olanzapine and intramuscular haloperidol in acute schizophrenia: antipsychotic efficacy and extrapyramidal safety during the first 24 hours of treatment. Can J Psychiatry. 2003;48:716–21.PubMed
117.
Lindborg SR, Beasley CM, Alaka K, Taylor CC. Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients. Psychiatry Res. 2003;119(1–2):113–23.PubMed
118.
Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59:441–8.PubMed
119.
Di Lorenzo R, Brogli A. Profile of Olanzapine long-acting injection for the maintenance treatment of adult patients with schizophrenia. Neuropsychiat Dis Treat. 2010;6:573–81.
120.
Lindenmayer JP. Long-acting injectable antipsychotics: focus on olanzapine pamoate. Neuropsychiat Dis Treat. 2010;6:261–7.
121.
Luedecke D, Schöttle D, Karow A, Lambert M, Naber D. Post-Injection delirium/sedation syndrome in patients treated with olanzapine pamoate: mechanism, incidence, and management. CNS Drugs. 2015;29:41–6.PubMed
122.
Perry PJ, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients. J Clin Psychopharmacol. 1997;17:472–7.PubMed
123.
Kapur S, Zipursky RB, Remington G, Jones C, DaSilva J, Wilson AA, Houle S. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry. 1998;155:921–8.PubMed
124.
Attarbaschi T, Sacher J, Geiss-Granadia T, Klein N, Mossaheb N, Lanzenberger R, Asenbaum S, Dudczak R, Kasper S, Tauscher J. Striatal D2 receptor occupancy in bipolar patients treated with olanzapine. Eur Neuropsychopharmacol. 2007;17:102–7.PubMed
125.
Mauri MC, Maffini M, Di Pace C, Reggiori A, Paletta S, Moliterno D, Rovera C, Altamura AC. “Long-acting” olanzapine in maintenance therapy of schizophrenia: a study with plasma levels. Int J Psychiatry Clin Pract. 2015;19:99–105.PubMed
126.
McDonnell DP, Landry J, Detke HC. Long-term safety and efficacy of olanzapine long-acting injection in patients with schizophrenia or schizoaffective disorder: a 6-year, multinational, single-arm, open-label study. Int Clin Psychopharmacol. 2014;29:322–31.PubMedPubMedCentral
127.
Bergstrom R, Callaghan J, Cerimele J, Kurtz D, Hatcher B. Population pharmacokinetics and plasma concentrations of olanzapine. In: Tran P, Bymaster F, Tye N, Herra J, Breier A, Tollefson G, editors. Olanzapine (Zyprexa): a novel antipsychotic. Philadelphia (PA): Lippincott, Williams, and Wilkins; 2000. p. 232–52.
128.
Perry PJ, Lund BC, Sanger T, Beasley C. Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial. J Clin Psychopharmacol. 2001;21:14–20.PubMed
129.
Citrome L, Stauffer VL, Chen L, Kinon BJ, Kurtz DL, Jacobson JG, Bergstrom RF. Olanzapine plasma concentrations after treatment with 10, 20, and 40 mg/day in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol. 2009;29(3):278–83.PubMed
130.
Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo: the Seroquel Trial 13 Study Group. Biol Psychiatry. 1997;42:233–46.PubMed
131.
Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997;96:265–73.PubMed
132.
Small JG, Hirsch SRM, Arvanitis LA, Miller BG, Link CG. Quetiapine in patients with schizophrenia: a high- and low-dose double blind comparison with placebo. Arch Gen Psychol. 1997;54:549–57.
133.
DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet. 2001;40:509–22.PubMed
134.
Mauri MC, Fiorentini A, Volonteri LS, Beraldo S, Dell’Osso B, Valli I, Pirola R, Bareggi SR. Quetiapine in acute psychosis and personality disorders during hospitalization: assessment of a therapeutic range. Eur Neuropsychopharmacol. 2004;14(Suppl. 3):283–4.
135.
Davis PC, Wong J, Gevfert O. Analysis and pharmacokinetics of quetiapine and two metabolites in human plasma using reversed-phase HPLC with ultraviolet and electrochemical detection. J Pharm Biomed Analysis. 1999;20:271–82.
136.
Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia. Arch Gen Psychiatry. 2000;57:553–9.PubMed
137.
Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet. 2000;38:393–414.PubMed
138.
Grimm SW, Stams KR, Bui K. In vitro prediction of potential metabolic drug interaction for Seroquel. Schizophr Res. 1997;24:198.
139.
Gunasekara NS, Spencer CM. Quetiapine. A review of its use in schizophrenia. CNS Drugs. 1998;9:325–40.PubMed
140.
Grimm SW, Richtand NM, Winter HR, Stams KR, Reel SB. Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics. Br J Pharmacol. 2006;61:58–69.
141.
Thyrum PT, Fabre LF, Wong YWJ. Multiple dose pharmacokinetics of ICI 204,636 in schizophrenic men and women. Psychopharmacol Bull. 1996;32:525.
142.
Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61:331–9.PubMed
143.
Gefvert O, Bergstrom M, Langstrom B, Lundberg T, Lindstrom L, Yates R. Time course of central nervous dopamine D2 and 5HT2 receptor blockade and plasma drug concentration after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology. 1998;135:119–26.PubMed
144.
Fabre JR, Arvanitis L, Pultz J, Jones VM, Malick JB, Slotnick VB. ICI 204,636, a novel atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther. 1995;17:366–78.PubMed
145.
Gefvert O, Lundberg T, Wieselgren I, Bergstrom M, Langstrom B, Wiesel F, Lindstrom L. D2 and 5HT2a receptor occupancy of different doses of quetiapine in schizophrenia: a PET study. Eur Neuropsychopharmacol. 2001;11:105–10.PubMed
146.
Carriere P, Bonhomme D, Lemperiere T. Amisulpride has a superior risk/benefit profile to haloperidol in schizophrenia: results of a multicentre, double-blind study. Amisulpride Study Group. Eur Psychiatry. 2000;15:321–9.PubMed
147.
Perrault G, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: an antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther. 1997;280:73–82.PubMed
148.
Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, Oblin A, Gonon F, Carter C, Benavides J, Scatton B. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997;280(1):83–97.PubMed
149.
Kopecek M, Bares M, Svarc J, Dockery C, Horacek J. Hyperprolactinemia after low dose of amisulpride. Neuro Endocrinol Lett. 2004;25:419–22.PubMed
150.
Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002;17:1–13.PubMed
151.
Dufour A, Desanti C. Pharmacokinetics and metabolism of amisulpride. Ann Psychiatry. 1988;3:298–305.
152.
Bergemann N, Kopitz J, Kress KR, Frick A. Plasma amisulpride levels in schizophrenia or schizoaffective disorder. Eur Neuropsychopharmacol. 2004;14:245–50.PubMed
153.
Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother. 2002;36:839–51.PubMed
154.
Gunasekara NS, Spencer CM, Keating GM. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. CNS Drugs. 2002;16:645–52.PubMed
155.
Schmidt AW, Lebel. LA, Howard HR Jr, Zorn SH. Ziprasidone: a novel antipsychotic agent with a unique human receptor binding profile Eur J Pharmacol. 2001;425(3):197–201PubMed
156.
Miceli JJ, Wilner KD, Hansen RA, Johnson AC, Apseloff G, Gerber N. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol. 2000;49(Suppl. 1):5S–13S.PubMedPubMedCentral
157.
Wilner KD, Tensfeldt TG, Baris B, Smolarek TA, Turncliff RZ, Colburn WA. Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers. Br J Clin Pharmacol. 2000;49(Suppl. 1):15S–20S.PubMedPubMedCentral
158.
Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther. 2002;24:21–37.PubMed
159.
Beedham C, Miceli JJ, Obach RS. Ziprasidone metabolism, aldehyde oxidase, and clinical implications. J Clin Psychopharmacol. 2003;23:229–32.PubMed
160.
Prakash C, Kamel A, Gummerus J. Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions. Drug Metab Disp. 1997;25:863–72.
161.
Wilner KD, Demattos SB, Anziano RJ, Apseloff G, Gerber N. Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers. Br J Clin Pharmacol. 2000;49(Suppl. 1):43S–7S.PubMedPubMedCentral
162.
Preskorn SH. Pharmacokinetics and therapeutics of acute intramuscular ziprasidone. Clin Pharmacokinet. 2005;44:1117–33.PubMed
163.
Miceli JJ, Wilner KD, Swan SK, Tensfeldt TG. Pharmacokinetics, safety, and tolerability of intramuscular ziprasidone in healthy volunteers. J Clin Pharmacol. 2005;45(6):620–30.PubMed
164.
Mamo D, Kapur S, Shammi CM, Papatheodorou G, Mann S, Therrien F, Remington G. A PET study of dopamine D2 and serotonin 5-HT2 receptor occupancy in patients with schizophrenia treated with therapeutic doses of ziprasidone. Am J Psychiatry. 2004;161:818–25.PubMed
165.
Suckow RF, Fein M, Correll CU, Coope TB. Determination of plasma ziprasidone using liquid chromatography with fluorescence detection. J Chromatogr B Anal Technol Biomed Life Sci. 2004;799:201–8.
166.
Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology. 1999;20:491–505.PubMed
167.
Goff DC, Posever T, Herz L, Simmons J, Kletti N, Lapierre K, Wilner K, Law CG, Ko GN. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18:296–304.PubMed
168.
Mailman RB, Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? Curr Pharm Des. 2010;16(5):488–501.PubMedPubMedCentral
169.
170.
Yokoi F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacol. 2002;27:248–59.
171.
172.
Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol. 2005;45:89–93.PubMed
173.
DeLeon A, Patel NC, Crismon ML. Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther. 2004;26:649–66.PubMed
174.
Shirley M, Perry CM. Aripiprazole: a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs. 2014;74:1097–110.PubMed
175.
Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44:179–87.PubMed
176.
Kirschbaum KM, Müller MJ, Malevani J, Mobascher A, Burchardt C, Piel M, Hiemke C. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry. 2008;9(3):212–8.PubMed
177.
Mallikaarjun S, Kane JM, Bricmont P, Robert McQuade R, William Carson W, Sanchez R, Forbes RA, Fleischhacker WW. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281–8.PubMed
178.
Potkin SG, Raoufinia A, Mallikaarjun S, Bricmont P, Peters-Strickland T, Kasper W, Baker RA, Eramo A, Sanchez R, McQuade R. Safety and tolerability of once monthly aripiprazole treatment initiation in adults with schizophrenia stabilized on selected atypical oral antipsychotics other than aripiprazole. Curr Med Res Opin. 2013;29(10):1241–51.PubMed
179.
Otsuka Pharmaceutical Europe Ltd. Abilify Maintena® EU (aripiprazole). Full prescribing information. Wexham: Otsuka Pharmaceutical Europe Ltd; 2016.
180.
Otsuka Pharmaceutical Co., Ltd. Abilify Maintena® US (aripiprazole). Full prescribing information. Tokyo: Otsuka Pharmaceutical Co. Ltd; 2016.
181.
Raoufinia A, Peters-Strickland T, Nylander A-G, Baker RA, Eramo A, Jin N, Bricmont P, Repella J, McQuade RD, Hertel P, Larsen F. Aripiprazole once-monthly 400 mg: comparison of pharmacokinetics, tolerability, and safety of deltoid versus gluteal administration. Int J Neuropsychopharmacol. 2017;20(4):295–304.PubMedPubMedCentral
182.
Sanchez C, Arnt J, Dragsted N. Neurochemical and in vivo pharmacological profile of sertindole, a limbic selective neuroleptic compound. Drug Dev Res. 1992;22:239–50.
183.
Hyttel J, Nielsen JB, Nowak G. The acute effect of sertindole on brain 5HT2, D2 and α1 receptors (ex vivo radioreceptor binding studies). J Neural Transm Gen Sect. 1992;89:61–9.PubMed
184.
Perquin L, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs. 2004;18(Suppl. 2):19–30.PubMed
185.
Van Kammen DP, Mc Envoy JP, Targum SD, Kardatzke D, Sebree TB. A randomized, controlled, dose ranging trial of sertindole in patients with schizophrenia. Psychopharmacology. 1996;124:168–75.PubMed
186.
Kasper S, Tauscher J, Küfferle B, Barnas C, Heβelmann B, Asenbaum S, Podreka I, Brücke T. Sertindole and dopamine D2 receptor occupancy in comparison to risperidone, clozapine and haloperidol: a 123I-IBZM SPECT study. Psychopharmacology. 1998;136:367–73.PubMed
187.
Wilton LV, Heeley EL, Pickering RM, Shakir SA. Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine. J Psychopharmacol. 2001;15:120–6.PubMed
188.
Wong SL, Linnen P, Mack R, Granneman GR. Effect of food, antiacid, and dosage form on the pharmacokinetics and relative bioavailability of sertindole in healthy volunteers. Biopharm Drug Dispos. 1997;18:533–41.PubMed
189.
Wong SL, Granneman GR. Modeling of sertindole pharmacokinetic disposition in healthy volunteers in short term dose-escalation studies. J Pharm Sci. 1998;87:1629–31.PubMed
190.
Wong SL, Locke C, Staser J, Granneman GR. Lack of multiple dosing effects of sertindole on the pharmacokinetics of alprazolam in healthy volunteers. Psychopharmacology. 1998;135:236–41.PubMed
191.
Sakamoto K, Nakamura Y, Aikoh S, Baba T, Perregaard J, Pedersen H, Moltzen EK, Mulford DJ, Yamaguchi T. Metabolism of sertindole: identification of the metabolites in the rat and dog, and species comparison of liver microsomal metabolism. Xenobiotica. 1995;25:1327–43.PubMed
192.
Wong SL, Menacherry S, Mulford D, Schmitz PJ, Locke C, Granneman GR. Pharmacokinetics of sertindole and dehydrosertindole in volunteers with normal or impaired renal function. Eur J Pharmacol. 1997;52:223–7.
193.
Drici MD, Wang WX, Liu XK, Woosley RL, Flockhart DA. Prolongation of QT interval in isolated feline hearts by antipsychotic drugs. J Clin Psychopharmacol. 1998;18:477–81.PubMed
194.
Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry. 1997;154:782.PubMed
195.
Canal-Raffin M, Déridet E, Titier K, Frakra E, Molimard M, Moore N. Simplified ultraviolet liquid chromatographic method for determination of sertindole, dehydrosertindole and norsertindole, in human plasma. J Chromatogr B. 2005;814:61–7.
196.
Shiraga T, Kaneko H, Iwasaki K, Tozuka Z, Suzuki A, Hata T. Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, anantipsychotic drug, in human liver microsomes. Xenobiotica. 1999;29:217–29.PubMed
197.
Leysen JE, Janssen PM, Schotte A, Luyten WH, Megens AA. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology. 1993;112(1 Suppl.):S40–54.PubMed
198.
Prakash A, Lamb HM. Zotepine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of schizophrenia. CNS Drugs. 1998;9(2):153–75.
199.
Tatsumi M, Jansen K, Blakely RD, Richelson E. Pharmacological profile of neuroleptics at human monoamine transporters. Eur J Pharmacol. 1999;368:277–83.PubMed
200.
Fleischhacker WW, Barnas C, Stuppäck CH, Unterweger B, Miller C, Hinterhuber H. Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial. Psychopharmacol Bull. 1989;25:97–100.PubMed
201.
Kondo T, Otani K, Mihara K, Tanaka O, Kaneko S, Fukushima Y. A study of the therapeutic spectrum of a fixed dose of zotepine and its relationship with serum concentrations of the drug. Hum Psychopharmacol. 1993;8:133–9.
202.
Amann B, Sterr A, Mergl R, Dittmann S, Seemuller F, Dobmeier M, Orth M, Schaefer M, Grunze H. Zotepine loading in acute and severely manic patients: a pilot study. Bipolar Disord. 2005;7:471–6.PubMed
203.
Shobo M, Kondo Y, Yamada H, Mihara T, Yamamoto N, Katsuoka M, Harada K, Ni K, Matsuoka N. Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther. 2010;333(3):772–81.PubMed
204.
Ohki M, Morokawa Y, Yanagida H, Utagawa I, Morishima Y, Gen K, Sanaka T, Watanabe H, Ohta T, Kamimira M, et al. An evaluation of antiserotonine and antidopamine activities of zotepine and its metabolites. Int Clin Psychopharmacol. 1999;14:47.
205.
Heal DJ, Needham PL. Comparison of the pharmacological profiles of zotepine and norzotepine. Eur Neuropsychopharmacol. 1996;6:105.
206.
Saletu B, Grünberger J, Anderer P, Chwatal K. Relation between blood levels and average quantitative EEG and psychometrically assessed pharmacodynamic changes following zotepine [in German]. Fortschr Neurol Psychiatr. 1991;59(Suppl. 1):45–55.PubMed
207.
Tanaka O, Kondo T, Otani K, Yasui N, Tokinaga N, Kaneko S. Single oral dose kinetics of zotepine and its relationship to prolactin response and side effects. Ther Drug Monit. 1998;20(1):117–9.PubMed
208.
Kondo T, Otani K, Ishida M, Tanaka O, Kaneko S, Fukushima Y. Adverse effects of zotepine and their relationship to serum concentrations of the drug and prolactin. Ther Drug Monit. 1994;16(2):120–4.PubMed
209.
Ishida M. Therapeutic and adverse effects of zotepine and their relationships with serum kinetics of the drug [in Japanese]. Yakubutsu Seishin Kodo. 1993;13(3):97–105.PubMed
210.
Otani K, Kondo T, Kaneko S, Ishida M, Fukushima Y. Correlation between prolactin response and therapeutic effects of zotepine in schizophrenic patients. Int Clin Psychopharmacol. 1994;9(4):287–9.PubMed
211.
Green B. Zotepine: a clinical review. Expert Opin Drug Metab Toxicol. 2009;5(2):181–6.PubMed
212.
Szegedi A, Verweij P, van Duijnhoven W, Mackle M, Cazorla P, Fennema H. Meta analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J Clin Psychiatry. 2012;73(12):1533–40.PubMed
213.
Bobo WV. Asenapine, iloperidone and lurasidone: critical appraisal of the most recently approved pharmacotherapies for schizophrenia in adults. Expert Rev Clin Pharmacol. 2013;6(1):61–91.PubMed
214.
Peeters P, Bockbrader H, Spaans E, Dogterom P, Lasseter K, Marbury T, Gibson GL, de Greef R. Asenapine pharmacokinetics in hepatic and renal impairment. Clin Pharmacokinet. 2011;50(7):471–81.PubMed
215.
Reddy AVB, Venugopal N, Madhavi G. Simultaneous determination of asenapine and valproic acid in human plasma using LC-MS/MS: application of the method to support pharmacokinetic study. J Pharm Analysis. 2013;3(6):394–401.
216.
217.
Citrome L. Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism. Expert Opin Drug Metab Toxicol. 2014;10(6):893–903.PubMed
218.
Stahl SM, Cucchiaro J, Simonelli D, Hsu J, Pikalov A, Loebel A. Effectiveness of lurasidone for patients with schizophrenia following 6 weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry. 2013;74:507–15.PubMed
219.
Harvey PD, Siu CO, Ogasa M, Loebel A. Effect of lurasidone dose on cognition in patients with schizophrenia: post hoc analysis of a long-term, double-blind continuation study. Schizoph Res. 2015;166:334–8.
220.
Luoni A, Macchi F, Papp M, Molteni R, Riva MA. Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex. Int J Neuropsychopharmacol. 2015;18(4):1–12.
221.
Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther. 2012;29(10):815–25.PubMed
222.
Murai T, Nakako T, Ikeda K, Ikejiri M, Ishiyama T, Taiga M. Lack of dopamine D4 receptor affinity contributes to the procognitive effect of lurasidone. Behav Brain Res. 2014;261:26–30.PubMed
223.
Citrome L. A Review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27:879–911.PubMed
224.
Caccia S, Pasina L, Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsych Dis Treat. 2012;8:155–68.
225.
Arif SA, Mitchell MM. Iloperidone: a new drug for the treatment of schizophrenia. Am J Health Syst Pharm. 2011;68(4):301–8.PubMed
226.
Rado JT, Janicak PG. Long-term efficacy and safety of iloperidone: an update. Neuropsychiat Dis Treat. 2014;10:409–15.
227.
Cutler AJ, Kalali AH, Mattingly GW, Kunovac J, Meng X. Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr. 2013;18(1):43–54.PubMed
228.
Shayegan DK, Stahl SM. Atypical antipsychotics: matching receptor profile to individual patient’s clinical profile. CNS Spectr. 2014;9(10 Suppl. 11):6–14.
229.
Jia M, Li J, He X, Mingzhou Liu M, Zhou Y, Fan Y, Li W. Simultaneous determination of iloperidone and its two active metabolites in human plasma by liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. J Chromatogr B. 2013;928:52–7.
230.
Citrome L. Iloperidone: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability, regulatory affairs, and an opinion. Expert Opin Drug Metab Toxicol. 2010;6(12):1551–64.PubMed
231.
Weiden PJ, Manning R, Wolfgang CD, Ryan JM, Mancione L, Han G, Ahmed S, Mayo MG. A randomized trial of iloperidone for prevention of relapse in schizophrenia: the REPRIEVE Study. CNS Drugs. 2016;30:735–47.PubMedPubMedCentral
232.
Durgam S, Cutler AJ, Lu K, Migliore R, Ruth A, Laszlovszky I, Németh G, Meltzer HY. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind placebo- and active- controlled trial. J Clin Psychiatry. 2015;76(12):1574–82.
233.
Seneca N, Finnema SJ, Laszlovszky I, Kiss B, Horváth A, Pásztor G, Kapás M, Gyertyán I, Farkas S, Innis RB, Halldin C, Gulyás B. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology. 2011;218(3):579–87.PubMedPubMedCentral
234.
Caccia S, Invernizzi RW, Nobili A, Pasina L. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag. 2013;9:319–28.PubMedPubMedCentral
235.
Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013;9(2):193–206.PubMed
236.
Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30(2):114–26.PubMed
237.
Citrome L. Cariprazine in bipolar disorder: clinical efficacy, tolerability, and place in therapy. Adv Ther. 2013;30(2):102–13.PubMed
238.
Stahl SM. Mechanism of action of cariprazine. CNS Spectr. 2016;21(2):123–7.PubMed
239.
Gyertyán I, Kiss B, Sághy K, Laszy J, Szabó G, Szabados T, Gémesi LI, Pásztor G, Zájer-Balázs M, Kapás M, Csongor EÁ, Domány G, Tihanyi K, Szombathelyi Z. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents. Neurochem Int. 2011;59:925–35.PubMed
240.
Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry. 2003;53(3):193–203.PubMed
241.
Ohno Y. Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson’s disease. CNS Neurosci Ther. 2011;17:58–65.PubMed
242.
Nakamura T, Kubota T, Iwakaji A, Imada M, Kapás M, Morio Y. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment). Drug Des Dev Ther. 2016;10:327–38.
243.
Actavis. Cariprazine. Full prescribing information. Actavis; 2015.
244.
Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A, Pehrson AL, Hentzer M, Nielsen V, Bundgaard C, Arnt J, Stensbøl TB, Kikuchi T. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350(3):589–604.PubMed
245.
Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, Nyilas M, Carson WH, Sanchez R, Eriksson H. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172:870–80.PubMed
246.
Citrome L, Stensbøl TB, Maeda K. The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Expert Rev Neurother. 2015;15(10):1219–29.PubMed
247.
McKeage K. Adjunctive brexpiprazole: a review in major depressive disorder. CNS Drugs. 2016;30(2):91–9.PubMed
248.
Frankel Joshua S, Schwartz Thomas L. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol. 2017;7(1):29–41.PubMed
249.
Das S, Barnwal P, Winston AB, Mondal S, Saha I. Brexpiprazole: so far so good. Ther Adv Psychopharmacol. 2016;6(1):39–54.PubMedPubMedCentral
250.
Ishigooka J, Iwashita S, Higashi K, Liew EL, Tadori Y. Pharmacokinetics and safety of brexpiprazole following multiple-dose administration to Japanese patients with schizophrenia. J Clin Pharmacol. 2018;58(1):74–80.PubMed
251.
Liu HC, Chang WH, Wei FC, Lin SK, Lin SK, Jann MW. Monitoring of plasma clozapine levels and its metabolites in refractory schizophrenic patients. Ther Drug Monit. 1996;18:200–7.PubMed
252.
Mauri MC, Volonteri LS, Dell’Osso B, Regispani F, Papa P, Baldi M, Bareggi SR. Predictors of clinical outcome in schizophrenic patients responding to clozapine. J Clin Psychopharmacol. 2003;23:1–5.
253.
Dettling M, Sachse C, Brockmoller J, Schley J, Muller-Oerlinghausen B, Pickersgill I, Rolfs A, Schaub RT, Schmider J. Long-term therapeutic drug monitoring of clozapine and metabolites in psychiatric in- and outpatients. Psychopharmacology. 2000;152:80–6.PubMed
254.
Spina E, Avenoso A, Facciolà G, Scordo MG, Ancione M, Madia AG, Ventimiglia M, Perucca E. Relationship between plasma concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology. 2000;148:83–9.PubMed
255.
Van der Zwaag C, McGee M, McEnvoy JP, Freudenreich O, Wilson WH, Copper TB. Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry. 1996;153:1579–84.
256.
Centorrino F, Baldessarrini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JC. Clozapine and metabolites: concentrations in serum and clinical findings durino treatment of cronically psychotic patients. J Clin Psychopharmacol. 1994;14:119–25.PubMed
257.
Olesen OV, Thomsen K, Jensen PN, Wulff CH, Rasmussen NA, Refshammer C, Soresen J, Bysted M, Christensen J, Rosenberg R. Clozapine serum levels and side effects during steady state treatment of schizophrenic patients: a cross-sectional study. Psychopharmacology. 1995;117:371–8.PubMed
258.
Yoshimura R, Ueda N, Nakamura J. Possible relationship between combined plasma concentrations of risperidone plus 9-hydroxyrisperidone and extrapyramidal symptoms. Neuropsychobiology. 2001;44:129–33.PubMed
259.
Anderson C, True J, Ereshefsky L, Miller A. Risperidone clinical efficacy: role of the metabolite 9-OH-risperidone. Psychopharmacol Bull. 1994;30(1):88.
260.
Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, Baumann P. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. Am J Psychiatry. 1998;155:499–504.PubMed
261.
Lee HS, Tan CH, Khoo YM, Chee KT, Wong KE, Chong SA, Mahendran R, Yap JL, Low BL, Choo CH, Chan A. Serum concentrations and clinical effects of Risperidone in schizophrenic patients in Singapore: a preliminary report. Br J Clin Pharmacol. 1999;47:460–1.PubMed
262.
Horvitz-Lennon M, Mattke S, Predmore Z, Howes OD. The role of antipsychotic plasma levels in the treatment of schizophrenia. Am J Psychiatry. 2017;174(5):421–6.PubMed
263.
Patteet L, Morrens M, Maudens KE, Niemegeers P, Sabbe B, Neels H. Therapeutic drug monitoring of common antipsychotics. Ther Drug Monit. 2012;34:629–51.PubMed
264.
Grundmann M, Kacirova I, Urinovska R. Therapeutic drug monitoring of atypical antipsychotic drugs. Acta Pharm. 2014;64:387–401.PubMed
265.
Wang L, Yu L, Zhang AP, Fang C, Du J, Gu NF, Qin SY, Feng GY, Li XW, Xing QH, He L. Serum prolactin levels, plasma risperidone levels, polymorphism of cytochrome P450 2D6 and clinical response in patients with schizophrenia. J Psychopharmacol. 2007;21(8):837–42.PubMed
266.
Lostia AM, Mazzarini L, Pacchiarotti I, Lionetto L, De Rossi P, Sanna L, Sani G, Kotzalidis GD, Girardi P, Simmaco M, Tatarelli R. Serum levels of risperidone and its metabolite, 9-hydroxyrisperidone: correlation between drug concentration and clinical response. Ther Drug Monit. 2009;31(4):475–81.PubMed
267.
Yasui-Furukori N, Saito M, Nakagami T, Furukori H, Suzuki A, Kondo T, Kaneko S. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J Psychopharmacol. 2010;24(7):987–94.PubMed
268.
Lu ML, Chen CH, Kuo PT, Lin CH, Wu TH. Application of plasma levels of olanzapine and N-desmethyl-olanzapine to monitor metabolic parameters in patients with schizophrenia. Schizophr Res. 2018;193:139–45.PubMed
269.
Aichhorn W, Marksteiner I, Walch T, Zernig G, Saria A, Kemmler G. Influence of age, gender, body weight and valproate comedication on quetiapine plasma concentrations. lnt Clin Psychopharmacol. 2006;21(2):81–5.PubMed
270.
Dragicevic A, Muller MJ, Sachse J, Härtter S, Hiemke C. Therapeutic drug monitoring (TDM) of quetiapine. Lecture presented at the Symposium of the AGNP. Munich; 2003.
271.
Dragicevic A, Sachse J, Härtter S, Hiemke C, Muller MJ. Serum concentrations of quetiapine and clinical effects. International Meeting on Pharmacovigilance in Psychiatry. Therapeutic Drug Monitoring and Pharmacogenetics of Psychotropic Drugs. Lausanne; 2005.
272.
Dragicevic A, Trotzauer D, Hiemke C, Muller MJ. Gender and age effects on quetiapine serum concentrations in patients with schizophrenia or schizoaffective disorders. Lecture presented at the 24th Symposium of the AGNP. Munich; 2005.
273.
Mauri MC, Volonteri LS, Fiorentini A, Pirola R, Bareggi SR. Two weeks’ quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels. Expert Opin Pharmacother. 2007;8(14):2207–13.PubMed
274.
Gerlach M, Hünnerkopf R, Rothenhöfer S, Libal G, Burger R, Clement HW, Fegert JM, Wewetzer Ch, Mehler-Wex C. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry. 2007;40(2):72–6.PubMed
275.
Hasselstrøm I, Linnet K. Quetiapine serum concentrations in psychiatric patients: the influence of comedication. Ther Drug Monit. 2004;26(5):486–9.PubMed
276.
Albantakis L, Egberts K, Burger R, Kulpok C, Mehler-Wex C, Taurines R, Unterecker S, Wewetzer C, Romanos M, Gerlach M. Relationship between daily dose, serum concentration, and clinical response to quetiapine in children and adolescents with psychotic and mood disorders. Pharmacopsychiatry. 2017;50(6):248–55.PubMed
277.
Sparshatt A, Taylor D, Patel MX, Kapur S. A systematic review of aripiprazole dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. J Clin Psychiatry. 2010;71(11):1447–56.PubMed
278.
Lin SK, Chen CK, Liu YL. Aripiprazole and dehydroaripiprazole plasma concentrations and clinical responses in patientswith schizophrenia. J Clin Psychopharmacol. 2011;31(6):758–62.PubMed
Metadata
Title
Clinical Pharmacokinetics of Atypical Antipsychotics: An Update
Authors
Massimo Carlo Mauri
Silvia Paletta
Chiara Di Pace
Alessandra Reggiori
Giovanna Cirnigliaro
Isabel Valli
Alfredo Carlo Altamura
Publication date
01-12-2018
Publisher
Springer International Publishing
Published in
Clinical Pharmacokinetics / Issue 12/2018
Print ISSN: 0312-5963
Electronic ISSN: 1179-1926
DOI
https://doi.org/10.1007/s40262-018-0664-3

Other articles of this Issue 12/2018

Clinical Pharmacokinetics 12/2018 Go to the issue

Review article

Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole

Original Research Article

Clinical Investigation of Coproporphyrins as Sensitive Biomarkers to Predict Mild to Strong OATP1B-Mediated Drug–Drug Interactions

Original Research Article

A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life

Original Research Article

Predicting Escitalopram Exposure to Breastfeeding Infants: Integrating Analytical and In Silico Techniques

Original Research Article

Infliximab Pharmacokinetics are Influenced by Intravenous Immunoglobulin Administration in Patients with Kawasaki Disease

Original Research Article

Identification of Cytochrome P450-Mediated Drug–Drug Interactions at Risk in Cases of Gene Polymorphisms by Using a Quantitative Prediction Model